authors
- Laurie, Scott A
- Arnold, Andrew
- Shepherd, Frances A
- Dediu, Mircea
- Ciuleanu, Tudor
- Fenton, David
- Zukin, Mauro
- Goss, Glenwood
- Ding, Keyue
- Seymour, Lesley
Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]
Conferences
- Overview
- Research
- Additional Document Info
- View All
Overview
status
publication date
- September 1, 2009
has subject area
- 1102 Cardiorespiratory Medicine and Haematology (FoR)
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Thoracic Oncology Journal